In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Diagnostic Products Corp.: Thriving, For Now

Executive Summary

The popularity of DPC's random-access immunoassay system, the Immulite 2000, has helped the company become a significant player in the highly competitive automated immunoassay market. But DPC's benefited from some good luck--namely the misfortunes of top player Abbott Diagnostics and the slow efforts by other competitors to step into the gap left by Abbott. DPC's dilemma is whether it can maintain its narrow focus as Abbott re-emerges and other competitors get stronger.

You may also be interested in...



bioMerieux, a Family-Owned French Firm, Finally Goes Public

In early July, the family-owned French firm bioMerieux SA launched an IPO by listing a third of its shares on the French bourse. The offering has been a success, primarily enabling a restless shareholder to sell its stake. And while the microbiology company didn't raise money for itself, it will have to change its corporate culture, opening its books to the public for the first time and requiring it to be responsive to shareholders.

bioMerieux, a Family-Owned French Firm, Finally Goes Public

In early July, the family-owned French firm bioMerieux SA launched an IPO by listing a third of its shares on the French bourse. The offering has been a success, primarily enabling a restless shareholder to sell its stake. And while the microbiology company didn't raise money for itself, it will have to change its corporate culture, opening its books to the public for the first time and requiring it to be responsive to shareholders.

An Independent Pharmacia Diagnostics Charts an Independent Course

Two private equity firms' acquisition of Pharmacia Diagnostics from Pfizer underscores private equity's growing but still selective interest in European health care and opportunities in a field overlooked by mainstream diagnostics companies, allergy testing. The new owners are paying nearly $600 million in a bet on Pharmacia Diagnostics' long-time management's ability to take advantage of the growth potential of this specialized field.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

IV002101

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel